Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Courses Quicksearch

Search Now!


PH In Its Most Common Forms: Clinical Vignettes for WHO Groups 1, 2, and 4

Vinicio de Jesus Perez

Bonnie Hudak

Tim Lahm


  Sign in to add a review

Leave a Comment

Course ID: 2915

CME Information

Course Title

PH in Its Most Common Forms: Clinical Vignettes in WHO Groups 1, 2, and 4 PH


This information-intensive, clinical vignette provides an overview of pulmonary hypertension (PH) as it most commonly presents itself using clinical case studies. This previously recorded live webinar presents and examines WHO Groups 1 PH (PAH, pulmonary arterial hypertension); WHO Group 2 PH (PH due to left heart disease); and WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) offering an interesting perspective on topics in health care barriers, common diagnostic pitfalls, and the complexities of pediatric PH.

Course Authors

Tim Lahm, M.D.
Associate Professor of Medicine
Indiana University
Bloomington, Ind.

Vinicio de Jesus Perez, M.D.
Assistant Professor of Medicine
Stanford University
Stanford, Calif.

Bonnie Hudak, M.D.
Assistant Professor
Mayo Medical School
Jacksonville, Fla.

Content Reviewer

Murali Chakinala, M.D.
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, Mo.

CME Reviewer

Allyson R. Zazulia, M.D.
Associate Dean, Continuing Medical Education
Washington University School of Medicine in St. Louis
St. Louis, Mo.

Intended Audience

This activity has been designed for pulmonologists, cardiologists, rheumatologists, internists, and primary care physicians, as well as nurses, physician assistants, and other allied health professionals who help care for patients with pulmonary hypertension (PH). This activity is designed to improve knowledge, competence, performance, and patient care practices by instructing front-line clinicians in the highest quality of care for patients with PH.

Learning Objectives

At the conclusion of this activity participants should be able to:

  1. To recognize early symptoms of pulmonary hypertension (PH); 
  2. To recall that early symptoms of PH are non-specific and are often misdiagnosed as more common disorders;
  3. To be able to order and interpret appropriate studies to rule out the diagnosis of PH;
  4. Recognize signs and symptoms of pediatric pulmonary hypertension;
  5. Be able to explain how children with PH may not have any recognized predisposing condition; and
  6. Be able to plan the initial evaluation of a child with suspected PH.

Release Date

19 September 2017

Expiration Date

18 September 2019

Estimated Time to Complete This Activity

1 hour

Accreditation and Credit

ACCME Joint Accreditation

In support of improving patient care, this activity has been planned and implemented by Washington University School of Medicine in St. Louis, Continuing Medical Education and the Pulmonary Hypertension Association. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Education Provided by: Washington University School of Medicine in St. Louis, Continuing Medical Education.

Washington University designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1TM Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Earning Credit

This activity is a self-study program. Upon entering the activity, participants should read the text, examine any images and/or multimedia features, and review the content presented within all of the links provided. Once the course has been reviewed in its entirety, participants will be asked to complete a post-test and evaluation online. Participants must receive a test score of 80% in order to proceed to the course evaluation; the post-test can be repeated until all questions are answered correctly. All evaluation questions must be completed in order to receive a certificate of credit. If needed, participants may save their answers and complete the course at a later date. Saved courses can be found by using the "My Courses" link at the top of the page, and then click on "My Classes."

Disclosure Policy

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence the content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

All members of the CME department have nothing to disclose. Speakers are also expected to openly disclose the inclusion of any discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection, and analysis.

These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine. Washington University School of Medicine, Continuing Medical Education, is the provider of CME credits.

Disclosures are reported below:

  • Tim Lahm, M.D. receives reagents from Eli Lilly. He is also a member of a Speaker's Bureau for Bayer HealthCare.
  • Vinicio de Jesus Perez, M.D. has nothing to disclose
  • Bonnie Hudak, M.D. has nothing to disclose
  • Murali Chakinala, M.D. has received Research Support/Grants from Actelion Pharmaceuticals, Bayer HealthCare, Gilead Sciences, Novartis, Ikaria, Medtronic, and United Therapeutics. He has served as Consultant for Actelion Pharmaceuticals, Bayer HealthCare, United Therapeutics, Gilead Sciences, and SteadyMed. He served in Speakers' Bureaus or received Honoraria from Gilead Sciences and United Therapeutics
  • Allyson R. Zazulia, M.D. has no relevant financial disclosures


The information presented in this activity reflects the views of the faculty only and not necessarily those of the Pulmonary Hypertension Association (PHA), Washington University in St. Louis, or the educational grant providers. All participants should verify the information and data presented before treating patients or utilizing any therapies noted in these materials. No portion of this activity may be reproduced without the expressed written consent of PHA.

Technical Requirements

This course requires an internet browser. For optimum display, please use Mozilla Firefox, Safari or Google Chrome.

Privacy Policy

For information about PHA's privacy policy, visit

This activity is made possible through unrestricted educational grants to the PHA Medical Education Fund from Actelion Pharmaceuticals, US; Gilead Sciences, Inc.; and United Therapeutics Corporation.

©2017 Pulmonary Hypertension Association, 801 Roeder Road, Suite 1000, Silver Spring, MD 21910.